Cargando…
65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against Stenotrophomonas maltophilia (STM)
BACKGROUND: The current susceptibility breakpoint for MIN against STM is 4mg/L, yielding >99% of isolates susceptible. Unfortunately, there are limited pre-clinical and clinical data to support this breakpoint for STM. The purpose of this study was to evaluate the efficacy of a MIN human simulate...
Autores principales: | Fratoni, Andrew J, Nicolau, David P, Kuti, Joseph L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644019/ http://dx.doi.org/10.1093/ofid/ofab466.065 |
Ejemplares similares
-
1103. Minocycline (MIN) Pharmacodynamics (PD) against Stenotrophomonas maltophilia (STM) in a Neutropenic Murine Thigh Infection Model
por: Fratoni, Andrew J, et al.
Publicado: (2021) -
1584. Minocycline Activity Against Stenotrophomonas maltophilia Isolated From Patients in US Hospitals
por: Shortridge, Dee, et al.
Publicado: (2019) -
38. Predicting stenotrophomonas Maltophilia bloodstream Infections (BSI) in the Hematologic Malignancy Population
por: Karaba, Sara M, et al.
Publicado: (2020) -
2419. Standard vs. Alternative Therapy for Stenotrophomonas maltophilia Infections: Focus on Trimethoprim–Sulfamethoxazole, Minocycline, and Moxifloxacin Monotherapy
por: Badwal, Jasmin, et al.
Publicado: (2018) -
1366. In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas maltophilia Clinical Isolates
por: Ito, Akinobu, et al.
Publicado: (2018)